MorphoSys : Roche Receives Breakthrough Therapy Designation For Gantenerumab In Alzheimer's Disease

MorphoSys AG (MOR) said that its licensing partner Roche (RHHBY) received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, for the treatment of people living with Alzheimer's disease.

The designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of Alzheimer's disease, in the ongoing Scarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies.

MorphoSys noted that Roche is evaluating the safety and efficacy of gantenerumab in these two pivotal trials with more than 2,000 participants for more than two years. The trials are expected to be completed in the second half of 2022.

The FDA Breakthrough Therapy Designation is a process designed to expedite the development and review of drug candidates that are intended to treat serious or life-threatening conditions with preliminary evidence that indicates they may demonstrate a substantial improvement over available therapies that have received full FDA approval.

Gantenerumab is an investigational IgG1 antibody designed to bind to aggregated forms of beta-amyloid and remove brain amyloid plaques, a pathological hallmark of Alzheimer's disease.

The fully human monoclonal antibody was generated by MorphoSys using its proprietary HuCAL antibody technology. As per the terms of the licensing deal, Roche is fully responsible for the clinical development and potential commercialisation of gantenerumab.

MorphoSys is entitled to receive tiered royalties, ranging from 5.5% to 7.0%, on net product sales and potential success-based regulatory milestone payments related to gantenerumab.

MorphoSys will retain 40% of future royalties on gantenerumab, as outlined in the funding partnership between MorphoSys and Royalty Pharma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement. Specialized Bicycle Components, Inc. is recalling about 6,900 units of Tarmac SL7 Bicycles and Framesets for potential risk of fall and injury hazard, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the bicycle's fork steerer tube can crack or break after harsh impact such as hitting a deep pothole or other stress event, posing fall and injury hazards.
Follow RTT